AFP and hepatocellular carcinoma: Recently, PIVKA-II proposed to serve as a complementary or alternative diagnostic tool to AFP for HCC, while its diagnostic performance in detecting early-stage HCC was notably influenced by the underlying liver disease etiology (6).